



September 14, 2026

To whom it may concern:

Company Name: Innovacell Inc.
Representative: Representative Director Co-CEO
Colin Novick
Representative: Representative Director Co-CEO
Jason Sieger
(Code No.: 504A, Growth Market of the Tokyo Stock Exchange)
Point of Contact: Director CFO Yasushi Hosono
(<https://innovacell.com/contact/?lang=en>)

Notice Regarding Appearance on Nikkei CNBC's
“～攻めの IR～ Market Breakthrough”

We hereby announce that our Co-CEOs, Colin Lee Novick and Jason Sieger, will appear on the Nikkei CNBC program “～攻めの IR (Proactive IR)～ Market Breakthrough,” scheduled to air on Wednesday, September 16, 2026.

During the program, they will provide a detailed explanation of our business operations, strengths, and future growth strategies, alongside commentator Tetsuo Inoue and anchor Yukimi Yamada. We hope you'll tune in.



<Program details*>

Program name: Nikkei CNBC's “～攻めの IR～ Market Breakthrough”
Program website: https://www.nikkei-cnbc.co.jp/program/2001_semenoir
First air date: 11:40 am – 12:10 pm on Wednesday, September 16, 2026
Re-airing: 20:30 pm – 21:00 pm on Wednesday, September 16, 2026
18:30 pm – 19:00 pm on Friday, September 18, 2026
15:00 pm – 15:30 pm on Saturday, September 19, 2026
12:00 pm – 12:30 pm on Sunday, September 20, 2026

The program will be available for viewing on the YouTube channels listed below starting September 17, the day after it airs.

[Nikkei CNBC YouTube channel](#) 【～攻めのIR～Market Breakthrough】

[SBI Securities YouTube channel](#) 【Market Breakthrough】

*Please note that the broadcast is in Japanese only.

■ **About Innovacell Inc.** (<https://innovacell.com/?lang=en>)

The predecessor of Innovacell Inc. was a cell therapy start-up company spun out from the Medical University of Innsbruck (Austria). Innovacell Inc. was established in Japan in 2021 as the parent company of said Austrian company (currently Innovacell GmbH).

Innovacell group aims to improve patient health and quality of life (QOL) through the development and commercialization of cell therapies and regenerative medicine. It is currently focused on developing and commercializing regenerative medicine products for the treatment of urge and passive fecal incontinence as well as stress urinary incontinence.

ICEF15, the most advanced of the Group's pipeline products, aims to treat urge fecal incontinence by regenerating muscle tissue via the local administration of a patient's own skeletal myoblasts. ICEF15 is currently undergoing a multi-regional Phase III clinical trial in the U.S., 11 European countries, and Japan. To date, Innovacell GmbH has completed multiple clinical trials in Europe, including Phase IIb trials for ICEF15 (urge fecal incontinence) and ICES13 (stress urinary incontinence).

End